期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非清髓造血干细胞移植临床疗效

The Clinical Effect of Nonmyeloablative Hematopoietic Stem Cells Transplantation
下载PDF
导出
摘要 近年造血干细胞移植有了很大的发展,尤其是发展了非清髓造血干细胞移植(NST)。与传统的移植相比,非清髓造血干细胞移植能够减少急性移植物抗宿主病(GVHD)发生,减低预处理相关毒性,缩短粒细胞缺乏期,降低移植相关病死率。非清髓造血干细胞移植扩大了移植适应证,为血液病患者,尤其是老年患者提供了一条安全、有效、新的治疗手段。本文对近年非清髓造血干细胞移植治疗血液病的临床疗效简要综述。 Over the past several years, significant advancement has been achieved in hematopnietic stem cell transplantation, especially in nonmyeloablative stem cell transplantation （NST）. Compaed with traditional HSCT, NST can reduce acute GVHD, lower the toxicity related to fore treatment, shorten the time of agranulocytosis phase and decrease case fatality related to transplantation. It has enlarged transplantation indication, providing a new safty effective therapeutic method for elder patients. This review summarizes the clinical effect of NST in recent years.
作者 徐继 何志军 阮林海
机构地区 河南科技大学第一附属医院血液科
出处 《医学综述》 2006年第9期554-556,共3页 Medical Recapitulate
关键词 造血干细胞移植 非清髓性 恶性血液病 Hematopoietic stem cells transplantation Noymyeloablative Hematologic malignancies
分类号 R457.7 [医药卫生—治疗学]
  • 相关文献

参考文献20

  • 1郭梅,余长林,王丹红,乔建辉,孙万军,时葆赋,张石,孙琪云,姚波,艾辉胜.氟达拉滨和非氟达拉滨预处理方案在非清髓异基因造血干细胞移植中的比较[J].中华血液学杂志,2003,24(8):413-415. 被引量：6
  • 2Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor ceils with purine analog-containing chemotherapy:harnessing graft-versus leukemia without myeloablative therapy[J].Blood, 1997,89(12) :4531-4536.
  • 3Slavin S, Nagler A, Naparstek A, et al. Nonmyeloablative stem cell transplantion and cell therapy as an alternative to conventional bone marrow transplantion with lethal cytoreduction for the threatment of malignant and nonmalignant hematologyic diseases[J]. Blood, 1998, 91(3) :756-763.
  • 4Storb RF, Champlin R, Riddell SR, et al. Nonmyeloablative transplants for malignant disease[A]. Hematology[M]. Washigton : Am See Hematol Edut Program,2002,375-391.
  • 5Or R, Shapira MY, Resmick I, et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase[J] .Blood,2003,101(2) :441-445.
  • 6Uzunel M, Mattsson J, Brune M, et al. Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloeblative conditioning and allogeneic stem cell transplantation[J]. Blood,2003,101(2) :469-472.
  • 7余长林,艾辉胜,赵春华,王丹红,乔建辉,郭梅,张石,孙万军,姚波.非清髓性异基因外周血造血干细胞移植治疗慢性白血病七例报告[J].中华器官移植杂志,2003,24(5):261-263. 被引量：2
  • 8艾辉胜,余长林,王丹红,郭梅,乔建辉,时葆赋,孙万军,张石,孙琪云,姚波.非清髓异基因外周血造血干细胞移植治疗血液病的临床观察[J].中华血液学杂志,2003,24(2):86-89. 被引量：13
  • 9郭宏锋,乔振华,苏丽萍,葛晓燕,姜波,朱秋娟,李容萍.非清髓性异基因外周血造血干细胞移植[J].中华器官移植杂志,2003,24(5):264-266. 被引量：2
  • 10Shimoni A, Andelini B, Estcy E, et al. Allogeneic transplantation for leukemia in patients older than 60 years: age should not exolude treatment with nonmyeloablative regimen[J]. Blood, 1999,94 [Suppl 1]710a.

二级参考文献46

  • 1艾辉胜 余长林 王丹红 等.非清髓性异基因外周血干细胞移植治疗血液病10例报告[J].中华内科杂志,1999,23:74-74.
  • 2[1]Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood, 1997, 89 (12): 4531～4536
  • 3[2]Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood, 1999, 94(9):3234～3241
  • 4[3]Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alter native to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic dieases. Blood, 1998, 91(3):756～763.
  • 5[4]Siegert W, Beyer J, Kingreen D, et al. Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation. Bone Marrow Transplantation, 1998,22:579～583
  • 6[3]Shimoni A,Anderlini P,Andersson B et al. Allogeneic transplantation for leukemia in patients older than 60 years:age should not exclude treatment with nonmyeloablative regimen.Blood,1999,94(Suppl 1):710
  • 7[4]Storb RF, Champlin R, Riddell SR et al. Non-myeloablative transplants for malignant disease. Hematology (Am Soc Hematol Educ Program), 2001:375
  • 8[1]Khouri LF, Keating M, Korbling M et al. Transplant-lite: induction of gfaft-versus-maliganancy using fludabine-based nonblative chemotherapy and allogenetic blood progenitor-cell transplantation as treatment for lymphoid maligancies. J Clin Oncology, 1998,16:2 817
  • 9[2]Storb R, Zaucha CY, Deeg HJ. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig and 100cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood, 1999,94:2 523
  • 10Storb RF, Champlin R, Riddell S, et al. Non-myeloablative transplants for malignant disease.Hematology (2001 The American Society of Hematology Education Program Book). Washington. 2001. 375-391.

共引文献22

医学综述
2006年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部